)
)
Silvia-Elena Glont
Senior Scientist, Translational Genomics
,
AstraZeneca
Silvia Glont, Senior Scientist, AstraZeneca, Oncology R&D | Translational Medicine.
I completed my PhD at the University of Cambridge, focusing on the molecular mechanisms of endocrine resistance in ERα‑positive breast cancer in Prof. Jason Carroll’s lab at the CRUK Cambridge Institute. Following my PhD, I joined the CRUK Therapeutics Discovery Laboratory, gaining experience in target validation, disease positioning, and drug discovery.
In 2021, I became a Senior Scientist in Translational Medicine, Genomics at AstraZeneca. In this role, I have led genomics analyses for multiple AZ clinical trials, both internally and externally. I have also led capabilities development, ranging from bulk whole-transcriptome sequencing (WTS) on FFPE clinical samples to single-cell/single-nuclei analyses, and successfully implemented these methods in several clinical trials.
I completed my PhD at the University of Cambridge, focusing on the molecular mechanisms of endocrine resistance in ERα‑positive breast cancer in Prof. Jason Carroll’s lab at the CRUK Cambridge Institute. Following my PhD, I joined the CRUK Therapeutics Discovery Laboratory, gaining experience in target validation, disease positioning, and drug discovery.
In 2021, I became a Senior Scientist in Translational Medicine, Genomics at AstraZeneca. In this role, I have led genomics analyses for multiple AZ clinical trials, both internally and externally. I have also led capabilities development, ranging from bulk whole-transcriptome sequencing (WTS) on FFPE clinical samples to single-cell/single-nuclei analyses, and successfully implemented these methods in several clinical trials.
Sessions
-
From FFPE to Insight: 10x FLEX scRNA‑seq for MoA, Resistance, and Patient Stratification29-Jan-2026Precision Medicine & Patient Stratification Stage